August 15, 2025International Journal of ObesityOpen Access

Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics

View Full Paper

Ask AI

Bookmark

Authors

JVJithin Sam Varghese DGDavid Goldsmith RCRobert O. Cotes

Discussion

Member takes

Implication

Retrospective cohort study evaluates weight loss outcomes in patients prescribed second-generation antipsychotics, highlighting differences in efficacy based on antipsychotic weight gain categories.

Key Points

Those prescribed incretin-based medications lost an average of −2.17 kg after 6 months, indicating significant potential for weight management.
Individuals taking low AIWG antipsychotics experienced greater weight loss of −3.02 kg, compared to −1.33 kg in high AIWG groups.
The study analyzed a sample of 66,574 adults using electronic health records, focusing on the effects of incretin medications.
Findings suggest that incretin-based medications like semaglutide and tirzepatide may be less effective in patients on medications that cause higher weight gain.

Cite This Study

Varghese et al. (2025) studied this question.

synapsesocial.com/papers/68af2d6fcf1dd9ea359e504c https://doi.org/10.1038/s41366-025-01885-4

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study evaluates weight loss outcomes in patients prescribed second-generation antipsychotics, highlighting differences in efficacy based on antipsychotic weight gain categories.